GSK is putting the finishing touches on its case for antibody-drug conjugate Blenrep with a key progression-free survival ...

"NICE approves GSK’s belantamab mafodotin for blood cancer" was originally created and published by Pharmaceutical Technology ...

England is the first country in the world to make GSK's anti-BCMA drug Blenrep available to patients with the haematological ...

GSK’s Blenrep (belantamab mafodotin) has been recommended by the National Institute for Health and Care Excellence (NICE) as ...

A “TROJAN HORSE” therapy that sneaks toxic drugs inside and kills cancer cells is being rolled out on the NHS in England in a ...

It has been dubbed a “Trojan horse” treatment because it works by being taken into a cancer cell, before releasing a high ...

Blenrep, which is predicted by analysts to produce revenues of around $1.5bn in 2026, is an antibody-drug conjugate that works by targeting B-cell maturation antigen (BCMA), a protein commonly ...

The targeted therapy can stop myeloma from progressing by nearly three times as long as existing treatments, studies suggest.

Terminal patients could get years more with their loved ones as the NHS offers Blenrep, which can put some blood cancer patients in remission ...

The National Institute for Health and Care Excellence (NICE) has issued a draft guidance recommending GSK’s Blenrep (belantamab mafodotin) in combination with bortezomib and dexamethasone (BVd) for ...

Cookies are files saved on your phone, tablet or computer when you visit a website. We use cookies to store information about how you use the NICE website and services, such as the pages you visit.

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a positive opinion for Blenrep (belantamab mafodotin) for the treatment of relapsed or ...